A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) (PROTECT)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01235962
First received: October 14, 2010
Last updated: January 16, 2014
Last verified: January 2014
  Purpose

This randomized Phase III study is to evaluate whether pazopanib compared with placebo can prevent or delay recurrence of kidney cancer in patients with moderately high or high risk of developing recurrence after undergoing kidney cancer surgery


Condition Intervention Phase
Cancer
Drug: pazopanib
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Disease-free survival [ Time Frame: approximately 6 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival [ Time Frame: approximately 9 years ] [ Designated as safety issue: No ]
  • Disease-free survival rates at yearly time points (e.g. 1 year, 2 years, etc.). [ Time Frame: yearly for 4 or 5 years ] [ Designated as safety issue: No ]
  • Safety (frequency and severity of adverse events and laboratory abnormalities) [ Time Frame: approximately 12 months ] [ Designated as safety issue: Yes ]
  • Health Outcome (change from baseline in patients' self-reports on health outcome and quality of life as measured by two instruments: Cancer Therapy-Kidney Symptom Index-19 and EuroQOL-5D [ Time Frame: approximately 6 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 1500
Study Start Date: November 2010
Estimated Study Completion Date: April 2019
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: pazopanib
Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
Drug: pazopanib
Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
Other Name: Votrient
Placebo Comparator: placebo
placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
Drug: placebo
placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed written informed consent
  • Diagnosis of RCC with clear-cell or predominant clear-cell histology
  • Subjects with non-metastatic disease (M0) fulfilling any of the following combinations of pathologic staging based on American Joint Committee on Cancer (AJCC) TNM staging version 2010 and Fuhrman nuclear grading.

    • pT2, G3 or G4, N0; or,
    • pT3, G any, N0; or,
    • pT4, G any, N0; or,
    • pT any, G any, N1
  • Fulfill all of the following criteria of disease-free status at baseline:

    • Had complete gross surgical resection of all RCC via radical or partial nephrectomy using either open or laparoscopic technique.
    • Baseline imaging of chest, abdomen and pelvis shows no metastasis or residual tumor lesions as confirmed centrally by an independent radiologist.
  • Received no prior adjuvant or neo-adjuvant treatment for RCC
  • Recovered from nephrectomy: any surgery related toxicities should be reduced to ≤ grade 1 per NCI Common Terminology Criteria for Adverse Events (CTCAE) (Version 4)
  • Karnofsky performance scale (KPS) of ≥ 80
  • Adequate organ system function

Exclusion Criteria:

  • History of another malignancy. Exception: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible
  • Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to:

    • Active peptic ulcer disease
    • Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation
    • History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment
  • Active diarrhea of any grade
  • Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to:

    • Malabsorption syndrome
    • Major resection of the stomach or small bowel
  • History of human immunodeficiency virus (HIV) infection
  • History of active hepatitis
  • Presence of uncontrolled infection.
  • History of any one or more of the following cardiovascular conditions within the past 6 months:

    • Cardiac angioplasty or stenting
    • Myocardial infarction
    • Unstable angina
    • Coronary artery bypass graft surgery
    • Symptomatic peripheral vascular disease
  • History of Class III or IV congestive heart failure, as defined by the New York Heart Association Classification of Congestive Heart Failure
  • History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
  • Corrected QT interval (QTc) > 480 milliseconds (msec)
  • Poorly controlled hypertension, defined as systolic blood pressure (SBP) of ≥140 mmHg or diastolic blood pressure (DBP) of ≥ 90mmHg.

Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. Blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP values from each BP assessment must be <140/90 mmHg in order for a subject to be eligible for the study (see Section 7.6.2 for instruction on blood pressure measurement and obtaining mean blood pressure values).

  • Evidence of active bleeding or bleeding diathesis
  • Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures
  • Unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study treatment and for the duration of the study.
  • Concurrent therapy given to treat cancer including treatment with an investigational agent or concurrent participation in another clinical trial involving anti-cancer investigational drug.
  • Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study treatment.
  • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that in the opinion of the investigator contraindicates their participation.
  • Prior or current use of systemic anti-VEGF inhibitors, cytokines (e.g. interferon, interleukin 2).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01235962

  Hide Study Locations
Locations
United States, Arkansas
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
United States, California
GSK Investigational Site
Beverly Hills, California, United States, 90211
GSK Investigational Site
Fresno, California, United States, 93720
GSK Investigational Site
Hayward, California, United States, 94545
GSK Investigational Site
La Jolla, California, United States, 92093
GSK Investigational Site
Los Angeles, California, United States, 90089
GSK Investigational Site
Los Angeles, California, United States, 90033
GSK Investigational Site
Los Angeles, California, United States, 90095
GSK Investigational Site
Los Angeles, California, United States, 90048-0750
GSK Investigational Site
Oakland, California, United States, 94611
GSK Investigational Site
Roseville, California, United States, 95661
GSK Investigational Site
Sacramento, California, United States, 95825
GSK Investigational Site
San Francisco, California, United States, 94115
GSK Investigational Site
San Jose, California, United States, 95119-1110
GSK Investigational Site
Santa Clara, California, United States, 95051
GSK Investigational Site
South San Francisco, California, United States, 94080
GSK Investigational Site
Stanford, California, United States, 94305
GSK Investigational Site
Vallejo, California, United States, 94589
GSK Investigational Site
Walnut Creek, California, United States, 94596
United States, Colorado
GSK Investigational Site
Ft. Collins, Colorado, United States, 80528
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20007
United States, Florida
GSK Investigational Site
Fort Myers, Florida, United States, 33916
GSK Investigational Site
Tampa, Florida, United States, 33612
United States, Georgia
GSK Investigational Site
Athens, Georgia, United States, 30607
GSK Investigational Site
Macon, Georgia, United States, 31201
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60637
United States, Indiana
GSK Investigational Site
Indianapolis, Indiana, United States, 46202
United States, Iowa
GSK Investigational Site
Iowa City, Iowa, United States, 52242
United States, Maryland
GSK Investigational Site
Baltimore, Maryland, United States, 21287
United States, Massachusetts
GSK Investigational Site
Boston, Massachusetts, United States, 02115
GSK Investigational Site
Boston, Massachusetts, United States, 02114
GSK Investigational Site
Boston, Massachusetts, United States, 02215
GSK Investigational Site
Burlington, Massachusetts, United States, 01805
United States, Michigan
GSK Investigational Site
Detroit, Michigan, United States, 48201
United States, Minnesota
GSK Investigational Site
Rochester, Minnesota, United States, 55905
GSK Investigational Site
St. Louis Park, Minnesota, United States, 55426
United States, Missouri
GSK Investigational Site
St. Louis, Missouri, United States, 63110
United States, Nebraska
GSK Investigational Site
Lincoln, Nebraska, United States, 68510
GSK Investigational Site
Omaha, Nebraska, United States, 68198
GSK Investigational Site
Omaha, Nebraska, United States, 68114
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89169
United States, New Jersey
GSK Investigational Site
Hackensack, New Jersey, United States, 07601
United States, New York
GSK Investigational Site
Albany, New York, United States, 12206
GSK Investigational Site
Buffalo, New York, United States, 14263
GSK Investigational Site
New York, New York, United States, 10019
GSK Investigational Site
New York, New York, United States, 10065
GSK Investigational Site
New York, New York, United States, 10021
GSK Investigational Site
New York, New York, United States, 10003
United States, North Carolina
GSK Investigational Site
Durham, North Carolina, United States, 27710
United States, Ohio
GSK Investigational Site
Cincinnati, Ohio, United States, 45242
GSK Investigational Site
Cleveland, Ohio, United States, 44195
GSK Investigational Site
Columbus, Ohio, United States, 43210
United States, Oregon
GSK Investigational Site
Portland, Oregon, United States, 97213
GSK Investigational Site
Springfield, Oregon, United States, 97477
United States, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19106
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19107
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19111
United States, Rhode Island
GSK Investigational Site
Providence, Rhode Island, United States, 02903
GSK Investigational Site
Providence, Rhode Island, United States, 02906
United States, South Carolina
GSK Investigational Site
Charleston, South Carolina, United States, 29425
United States, Tennessee
GSK Investigational Site
Chattanooga, Tennessee, United States, 37404
GSK Investigational Site
Memphis, Tennessee, United States, 38120
GSK Investigational Site
Nashville, Tennessee, United States, 37232-5536
GSK Investigational Site
Nashville, Tennessee, United States, 37203
United States, Texas
GSK Investigational Site
Bedford, Texas, United States, 76022
GSK Investigational Site
Dallas, Texas, United States, 75246
GSK Investigational Site
Houston, Texas, United States, 77024
GSK Investigational Site
Houston, Texas, United States, 77030
GSK Investigational Site
San Antonio, Texas, United States, 78217
GSK Investigational Site
Tyler, Texas, United States, 75702
United States, Virginia
GSK Investigational Site
Hampton, Virginia, United States, 23666
GSK Investigational Site
Richmond, Virginia, United States, 23230
GSK Investigational Site
Virginia Beach, Virginia, United States, 23462
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98109
Argentina
GSK Investigational Site
Berazategui, Buenos Aires, Argentina, B1880BBF
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, C1426ANZ
GSK Investigational Site
Ciudad Aut6noma de Buenos Aires, Buenos Aires, Argentina, C1050AAK
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1280AEB
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1405BCH
GSK Investigational Site
Quilmes, Buenos Aires, Argentina, 1878
GSK Investigational Site
Córdoba, Córdova, Argentina, X5006HBF
GSK Investigational Site
Córdoba, Córdova, Argentina, X5003DCE
GSK Investigational Site
Cipolletti, Río Negro, Argentina, R8324EMB
GSK Investigational Site
Rosario, Santa Fe, Argentina, S2000KZE
GSK Investigational Site
San Miguel de Tucumán, Argentina, T4000IAK
GSK Investigational Site
Santa Fe, Argentina, 3000
Austria
GSK Investigational Site
Graz, Austria, 8036
GSK Investigational Site
Innsbruck, Austria, 6020
GSK Investigational Site
Salzburg, Austria, A-5020
GSK Investigational Site
Salzburg, Austria, 5020
GSK Investigational Site
Vienna, Austria, 1130
GSK Investigational Site
Vienna, Austria, A-1090
Belgium
GSK Investigational Site
Hasselt, Belgium, 3500
GSK Investigational Site
Jette, Belgium, 1090
GSK Investigational Site
Liège, Belgium, 4000
GSK Investigational Site
Namur, Belgium, 5000
GSK Investigational Site
Roeselare, Belgium, 8800
GSK Investigational Site
Wilrijk, Belgium, 2610
Brazil
GSK Investigational Site
Curitiba, Paraná, Brazil, 81520-060
GSK Investigational Site
Ijui, Rio Grande Do Sul, Brazil, 98700-000
GSK Investigational Site
Porto Alegre, Rio Grande Do Sul, Brazil, 90610000
GSK Investigational Site
Barretos, São Paulo, Brazil, 14784-400
GSK Investigational Site
Campinas, São Paulo, Brazil, 13083-970
GSK Investigational Site
Belo Horizonte, Brazil, 30.130-100
GSK Investigational Site
Rio de Janeiro, Brazil, 20231-050
GSK Investigational Site
Rio de Janeiro, Brazil, 20 551-030
GSK Investigational Site
São Paulo, Brazil, 01246-000
GSK Investigational Site
São Paulo, Brazil, 08270-070
GSK Investigational Site
São Paulo, Brazil, 01308-050
GSK Investigational Site
São Paulo, Brazil, 05651-901
Canada, Alberta
GSK Investigational Site
Calgary, Alberta, Canada, T2N 4N2
GSK Investigational Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
GSK Investigational Site
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, New Brunswick
GSK Investigational Site
Moncton, New Brunswick, Canada, E1C 6Z8
Canada, Nova Scotia
GSK Investigational Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
GSK Investigational Site
Hamilton, Ontario, Canada, L8V 5C2
GSK Investigational Site
London, Ontario, Canada, N6A 4L6
GSK Investigational Site
Oshawa, Ontario, Canada, L1G 2B9
GSK Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
GSK Investigational Site
Toronto, Ontario, Canada, M5G 2M9
GSK Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
GSK Investigational Site
Montreal, Quebec, Canada, H2L 4M1
Canada
GSK Investigational Site
Quebec, Canada, G1R 2J6
Chile
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7500921
GSK Investigational Site
Viña del Mar, Valparaíso, Chile, 254-0364
China, Hubei
GSK Investigational Site
Wuhan, Hubei, China, 430030
China, Zhejiang
GSK Investigational Site
Hangzhou, Zhejiang, China, 310003
GSK Investigational Site
Hangzhou, Zhejiang, China, 310009
China
GSK Investigational Site
Beijing, China, 100191
GSK Investigational Site
Beijing, China, 100034
GSK Investigational Site
Beijing, China, 100021
GSK Investigational Site
Beijing, China, 100853
GSK Investigational Site
Shanghai, China, 200040
GSK Investigational Site
Shanghai, China, 200127
GSK Investigational Site
Shanghai, China, 200025
GSK Investigational Site
Shanghai, China, 200032
GSK Investigational Site
Tianjin, China, 300060
Czech Republic
GSK Investigational Site
Brno, Czech Republic, 656 91
GSK Investigational Site
Brno, Czech Republic, 656 53
GSK Investigational Site
Hradec Kralove, Czech Republic, 500 05
GSK Investigational Site
Novy Jicin, Czech Republic, 741 01
GSK Investigational Site
Olomouc, Czech Republic, 775 20
GSK Investigational Site
Ostrava - Poruba, Czech Republic, 708 52
GSK Investigational Site
Plzen, Czech Republic, 304 60
GSK Investigational Site
Praha 2, Czech Republic, 12808
GSK Investigational Site
Praha 8, Czech Republic, 180 00
GSK Investigational Site
Usti nad Labem, Czech Republic, 40113
Denmark
GSK Investigational Site
Aarhus, Denmark, 8000 Aarhus C
GSK Investigational Site
DK-2730 Herlev, Denmark, 2730
GSK Investigational Site
Odense C, Denmark, 5000
France
GSK Investigational Site
Angers cedex 9, France, 49933
GSK Investigational Site
Besançon cedex, France, 25030
GSK Investigational Site
Bordeaux, France, 33075
GSK Investigational Site
Caen Cedex 05, France, 14076
GSK Investigational Site
Hyeres, France, 83400
GSK Investigational Site
Le Mans, France, 72000
GSK Investigational Site
Marseille cedex 5, France, 13385
GSK Investigational Site
Montpellier Cedex 5, France, 34295
GSK Investigational Site
Paris, France, 75014
GSK Investigational Site
Paris Cedex 15, France, 75908
GSK Investigational Site
Poitiers Cedex, France, 86021
GSK Investigational Site
Reims, France, 51100
GSK Investigational Site
Rennes, France, 35042
GSK Investigational Site
Saint Herblain, France, 44805
GSK Investigational Site
Strasbourg Cedex, France, 67091
GSK Investigational Site
Strasbourg cedex, France, 67085
GSK Investigational Site
Toulouse, France, 31076
GSK Investigational Site
Tours Cedex 9, France, 37044
Germany
GSK Investigational Site
Kirchheim, Baden-Wuerttemberg, Germany, 73230
GSK Investigational Site
Ravensburg, Baden-Wuerttemberg, Germany, 88212
GSK Investigational Site
Sigmaringen, Baden-Wuerttemberg, Germany, 72488
GSK Investigational Site
Stuttgart, Baden-Wuerttemberg, Germany, 70174
GSK Investigational Site
Tuebingen, Baden-Wuerttemberg, Germany, 72076
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89075
GSK Investigational Site
Erlangen, Bayern, Germany, 91054
GSK Investigational Site
Fuerth, Bayern, Germany, 90766
GSK Investigational Site
Muenchen, Bayern, Germany, 81675
GSK Investigational Site
Regensburg, Bayern, Germany, 93053
GSK Investigational Site
Weiden, Bayern, Germany, 92637
GSK Investigational Site
Frankfurt, Hessen, Germany, 60590
GSK Investigational Site
Marburg, Hessen, Germany, 35043
GSK Investigational Site
Offenbach, Hessen, Germany, 63069
GSK Investigational Site
Braunschweig, Niedersachsen, Germany, 38126
GSK Investigational Site
Goslar, Niedersachsen, Germany, 38642
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30625
GSK Investigational Site
Aachen, Nordrhein-Westfalen, Germany, 52074
GSK Investigational Site
Bergisch Gladbach, Nordrhein-Westfalen, Germany, 51465
GSK Investigational Site
Bonn, Nordrhein-Westfalen, Germany, 53127
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47179
GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany, 45122
GSK Investigational Site
Moenchengladbach, Nordrhein-Westfalen, Germany, 41063
GSK Investigational Site
Muenster, Nordrhein-Westfalen, Germany, 48149
GSK Investigational Site
Neuss, Nordrhein-Westfalen, Germany, 41464
GSK Investigational Site
Velbert, Nordrhein-Westfalen, Germany, 42551
GSK Investigational Site
Mainz, Rheinland-Pfalz, Germany, 55131
GSK Investigational Site
Homburg, Saarland, Germany, 66421
GSK Investigational Site
Dessau, Sachsen-Anhalt, Germany, 06846
GSK Investigational Site
Eisleben, Sachsen-Anhalt, Germany, 06295
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06120
GSK Investigational Site
Chemnitz, Sachsen, Germany, 09130
GSK Investigational Site
Leipzig, Sachsen, Germany, 04277
GSK Investigational Site
Plauen, Sachsen, Germany, 08523
GSK Investigational Site
Luebeck, Schleswig-Holstein, Germany, 23538
GSK Investigational Site
Jena, Thueringen, Germany, 07768
GSK Investigational Site
Berlin, Germany, 12200
GSK Investigational Site
Berlin, Germany, 10967
GSK Investigational Site
Berlin, Germany, 10719
GSK Investigational Site
Bremen, Germany, 28177
GSK Investigational Site
Hamburg, Germany, 20246
Greece
GSK Investigational Site
Athens, Greece, 115 22
GSK Investigational Site
Heraklion, Crete, Greece, 71100
GSK Investigational Site
Patra, Greece, 26504
GSK Investigational Site
Thessaloniki, Greece
Hungary
GSK Investigational Site
Budapest, Hungary, 1122
GSK Investigational Site
Budapest, Hungary, 1097
GSK Investigational Site
Budapest, Hungary, 1082
GSK Investigational Site
Miskolc, Hungary, 3526
GSK Investigational Site
Nyíregyháza, Hungary, 4400
GSK Investigational Site
Szombathely, Hungary, 9700
Ireland
GSK Investigational Site
Co.Cork, Ireland
GSK Investigational Site
Dublin, Ireland, 9
GSK Investigational Site
Dublin, Ireland, 7
GSK Investigational Site
Galway, Ireland
GSK Investigational Site
Tallaght, Dublin, Ireland, 24
Israel
GSK Investigational Site
Haifa, Israel, 31096
GSK Investigational Site
Jerusalem, Israel, 91120
GSK Investigational Site
Petach-Tikva, Israel, 49100
GSK Investigational Site
Rehovot, Israel, 76100
GSK Investigational Site
Tel Aviv, Israel, 64239
GSK Investigational Site
Zrifin, Israel, 70300
Italy
GSK Investigational Site
Napoli, Campania, Italy, 80131
GSK Investigational Site
Bologna, Emilia-Romagna, Italy, 40138
GSK Investigational Site
Meldola (FC), Emilia-Romagna, Italy, 47014
GSK Investigational Site
Modena, Emilia-Romagna, Italy, 41100
GSK Investigational Site
Roma, Lazio, Italy, 00144
GSK Investigational Site
Roma, Lazio, Italy, 00152
GSK Investigational Site
Milano, Lombardia, Italy, 20133
GSK Investigational Site
Pavia, Lombardia, Italy, 27100
GSK Investigational Site
Candiolo (TO), Piemonte, Italy, 10060
GSK Investigational Site
Arezzo, Toscana, Italy, 52100
GSK Investigational Site
Terni, Umbria, Italy, 05100
GSK Investigational Site
Negrar, Veneto, Italy, 37024
Japan
GSK Investigational Site
Fukuoka, Japan, 812-8582
GSK Investigational Site
Hokkaido, Japan, 060-8543
GSK Investigational Site
Hokkaido, Japan, 060-8648
GSK Investigational Site
Kanagawa, Japan, 236-0004
GSK Investigational Site
Okayama, Japan, 700-8558
GSK Investigational Site
Osaka, Japan, 589-8511
GSK Investigational Site
Shizuoka, Japan, 431-3192
GSK Investigational Site
Tokyo, Japan, 113-8603
GSK Investigational Site
Tokyo, Japan, 160-8582
GSK Investigational Site
Tokyo, Japan, 162-8666
GSK Investigational Site
Yamagata, Japan, 990-9585
Korea, Republic of
GSK Investigational Site
Daejeon, Korea, Republic of, 301-721
GSK Investigational Site
Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769
GSK Investigational Site
Jeonju, Korea, Republic of, 561-712
GSK Investigational Site
Seongnam-si Gyeonggi-do, Korea, Republic of, 463-707
GSK Investigational Site
Seoul, Korea, Republic of, 120-752
GSK Investigational Site
Seoul, Korea, Republic of, 136-705
GSK Investigational Site
Seoul, Korea, Republic of, 135-710
GSK Investigational Site
Seoul, Korea, Republic of, 110-744
GSK Investigational Site
songpa-gu, Seoul, Korea, Republic of, 138-736
Luxembourg
GSK Investigational Site
Luxembourg, Luxembourg, 1210
Poland
GSK Investigational Site
Gdansk, Poland, 80-219
GSK Investigational Site
Konin, Poland, 62-500
GSK Investigational Site
Krakow, Poland, 31-108
GSK Investigational Site
Krakow, Poland, 31-115
GSK Investigational Site
Lublin, Poland, 20-090
GSK Investigational Site
Warszawa, Poland, 02-781
GSK Investigational Site
Warszawa, Poland, 04-125
GSK Investigational Site
Warszawa, Poland, 02-776
GSK Investigational Site
Wroclaw, Poland, 50-556
Russian Federation
GSK Investigational Site
Arkhangelsk, Russian Federation, 163045
GSK Investigational Site
Barnaul, Russian Federation, 656049
GSK Investigational Site
Chelyabinsk, Russian Federation, 454087
GSK Investigational Site
Ekaterinburg, Russian Federation, 620102
GSK Investigational Site
Kazan, Russian Federation, 420029
GSK Investigational Site
Moscow, Russian Federation, 117997
GSK Investigational Site
Moscow, Russian Federation, 115478
GSK Investigational Site
Obninsk, Russian Federation, 249036
GSK Investigational Site
Omsk, Russian Federation, 644013
GSK Investigational Site
Rostov-na-Donu, Russian Federation
GSK Investigational Site
Ryazan, Russian Federation, 390011
GSK Investigational Site
Saint Petersburg, Russian Federation
GSK Investigational Site
St. Petersburg, Russian Federation, 197758
GSK Investigational Site
Stavropol, Russian Federation, 355047
GSK Investigational Site
Ufa,, Russian Federation, 450054
Slovakia
GSK Investigational Site
Banska Bystrica, Slovakia, 975 17
GSK Investigational Site
Bratislava, Slovakia, 833 05
GSK Investigational Site
Kosice, Slovakia, 041 66
GSK Investigational Site
Martin, Slovakia, 036 59
GSK Investigational Site
Zilina, Slovakia, 012 07
Spain
GSK Investigational Site
Badalona, Spain, 08916
GSK Investigational Site
Barcelona, Spain, 08035
GSK Investigational Site
Córdoba, Spain, 14004
GSK Investigational Site
Dos Hermanas (Sevilla), Spain, 41700
GSK Investigational Site
Madrid, Spain, 28007
GSK Investigational Site
Madrid, Spain, 28033
GSK Investigational Site
Madrid, Spain, 28041
GSK Investigational Site
Madrid, Spain, 28050
GSK Investigational Site
Málaga, Spain, 29010
GSK Investigational Site
Oviedo, Spain, 33006
GSK Investigational Site
Sevilla, Spain, 41013
GSK Investigational Site
Valencia, Spain, 46009
Turkey
GSK Investigational Site
Ankara, Turkey, 06590
GSK Investigational Site
Ankara, Turkey, 06100
GSK Investigational Site
Istanbul, Turkey, 34390
GSK Investigational Site
Izmir, Turkey, 35100
United Kingdom
GSK Investigational Site
Brighton, United Kingdom, BN2 5BE
GSK Investigational Site
Cornwall, United Kingdom, TR1 3LJ
GSK Investigational Site
Guildford, United Kingdom, GU2 7XX
GSK Investigational Site
London, United Kingdom, NW3 2QG
GSK Investigational Site
London, United Kingdom, SE1 9RT
GSK Investigational Site
Manchester, United Kingdom, M20 4BX
GSK Investigational Site
Preston, United Kingdom, PR2 9HT
GSK Investigational Site
Swansea, United Kingdom, SA2 8QA
GSK Investigational Site
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications:
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01235962     History of Changes
Other Study ID Numbers: 113387
Study First Received: October 14, 2010
Last Updated: January 16, 2014
Health Authority: Canada: Health Products and Foods Branch, Health Canada
Spain: Agencia Espanola de Medicamentos y Productos Sanitarios
Slovakia: State Institute for Drug Control
Argentina: Ministry of Health - A.N.M.A.T
Belgium: Agence Fédérale des Médicaments et des Produits de la Santé
Brazil: National Health Surveillance Agency
Italy: Agenzia Italiana del Farmaco
Chile:Ministerio de Salud de Chile
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Greece: National Organization of Medicines
Hungary: National Institute of Pharmacy
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Ireland: Irish Medicines Board
United States: Food and Drug Administration
Austria: Austrian Medicines and Medical Devices Agency (AGES PharmMed)
South Korea: Korea Food and Drug Administration (KFDA)
Germany: Bundesinstitut für Arzneimittel und Medizinprodukte
Denmark: Danish Medicines Agency
France: Agence Française de Sécurité Sanitaire des Produits de Santé
Russia: Ministry of Health of the Russian Federation
Japan: Pharmaceuticals and Medical Devices Agency
Israel: Ministry of Health
China: Food and Drug Administration
Europe: European Medicines Agency
Turkey: Ministry of Health
Czech Republic: State Institute for Drug Control

Keywords provided by GlaxoSmithKline:
anti-angiogenic agent
renal cell carcinoma
pazopanib
adjuvant therapy
VEGFR inhibitor

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on September 14, 2014